AMRX · Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals delivered robust Q1 2026 results, with net revenue reaching $723 million, up 4% from the prior year, propelled by a 23% surge in Specialty net revenue from key branded products like CREXONT®, the recent BREKIYA® autoinjector launch, and UNITHROID®. Affordable Medicines grew 2% on strong complex portfolio performance in women's health and ADHD, while AvKARE declined 4% due to a strategic shift from low-margin distribution to higher-margin government channels, boosting gross margin by 750 basis points and adjusted gross margin by 510 basis points. This portfolio optimization, alongside revenue growth, drove GAAP net income to $62 million (up 411%) and Adjusted EBITDA to $202 million (up 19%), with GAAP diluted EPS at $0.19 and adjusted at $0.27. Management highlighted entering the Kashiv transaction from strength, citing diversified growth drivers. The company affirmed its previously increased full-year 2026 guidance, including net revenue of $3.05-$3.15 billion, Adjusted EBITDA of $740-$770 million, and adjusted diluted EPS of $0.95-$1.05, signaling confidence in sustained momentum across core businesses despite forward-looking risks outlined in the release.